Open AccessLIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer
Author(s) -
Masahiro Tsuboi,
Jonathan W. Goldman,
YiLong Wu,
Melissa L. Johnson,
Luis PazAres,
James ChihHsin Yang,
Benjamin Besse,
Weiji Su,
Bo H. Chao,
Alexander Drilon
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0656
Subject(s) - medicine , oncology , clinical endpoint , lung cancer , population , durvalumab , cancer , placebo , clinical trial , radiation therapy , surgery , pathology , immunotherapy , nivolumab , alternative medicine , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom